A previously healthy 11-year-old Caucasian boy presented with a 2-week history of nonspecific symptoms of nausea and nonbilious, nonbloody emesis. He developed significant jaundice and hepatic encephalopathy within 1 week of beginning symptoms and was discovered to have fulminant liver failure. Extensive work-ups for underlying etiologies included serologic evaluation for underlying chronic liver diseases, toxicology screening, inborn errors of metabolism, and infectious diseases. The results of the entire assessment were negative except for human herpesvirus 6B, which was detected in the liver by quantitative real-time polymerase chain reaction and immunohistochemical analysis. The patient underwent ABO-compatible liver transplantation and has had clinically stable health, with no evidence to date of complications associated with HHV-6 or other members of the herpesvirus family.
DOI: 10.1093/labmed/lmx088 alanine aminotransferase (ALT), 1966 U per L; total bilirubin, 24.5 mg per dL; direct bilirubin, 23.0 mg per dL; and international normalized ratio (INR), 1.7 . Results of an acute hepatitis panel were negative, and the results of a liver ultrasound showed the liver size to be in the upper limits of normal for patient age; the patient was discharged to go home.
The following day, the patient developed a fever of 102° F and was taken to another facility; test results taken there showed worsening hepatic function and prompted transfer of the boy to our institution. On presentation, the results of laboratory testing revealed that the patient was experiencing acute liver failure. His laboratory values were as follows: AST, 3585 U per L; ALT, 2278 U per L; INR, 3.8; total bilirubin, 25.2 mg per dL; and direct bilirubin, 19 .44 mg per dL. An extensive work-up for underlying etiologies ruled out Wilson disease, autoimmune hepatitis, α-1 antitrypsin deficiency, vascular abnormalities, Coccidioides, human immunodeficiency virus (HIV), HSV I and II, Mycobacterium, respiratory syncytial virus (RSV), CMV, EBV, parvovirus B19, and influenza A and B. Also, the results of an acute hepatitis serology panel showed nonreactivity for hepatitis A immunoglobulin (Ig)M, hepatitis B surface antibody/antigen, hepatitis C antibody, and hepatitis E viral antibodies (IgG/IgM). Results of toxicology screening were negative. The only initial positive findings were rhinovirus/enterovirus detected in a nasopharyngeal swab and evidence of previous exposure to EBV with positive nuclear antigen antibody IgG and viral capsid antibody IgG.
A liver biopsy consisting of several needle cores (ranging in size from 0.15-1.7 cm) demonstrated acute hepatitis characterized by submassive hepatic necrosis and architectural collapse (Image 1A). Remnant hepatocytes displayed ballooning degeneration, distended and vacuolated cytoplasm, and vesicular nuclei, wherein focal intranuclear inclusions were noted (Image 1B). Conspicuous mixed inflammatory infiltrate comprised of macrophages and lymphocytes was present within portal areas, with spillage into the lobules. Ultrastructural analysis of the liver (Image 1C) recapitulated the histologic findings and failed to reveal an infectious etiology. Evaluation of the biopsy by immunohistochemistry (IHC) and qPCR for multiple agents, including HSV I and II, CMV, adenovirus, EBV, and hepatitis B, yielded negative results.
We were intrigued to discover that qPCR for HHV-6 performed on the core revealed a viral load of 1250 copies per mL (3.10 log). Given the positive qPCR result, the specimen was subjected to IHC analysis for HHV-6 (Coppe Laboratories, Waukesha, WI), the results of which revealed no immunoreactivity. HHV-6 was not detected in the plasma of our patient.
We treated the patient according to our ALF protocol, which included prophylactic antibiotics, antifungals, and acyclovir; the acyclovir was switched to valgancyclovir after detection of HHV-6 via qPCR. Despite maximal medical treatment, the residual liver function of the patient declined rapidly, his rising ammonia levels reached 241 µmol per L, and he developed worsening hepatic encephalopathy, stage 3 to 4. After liver transplant evaluation, he was listed as having status 1A and underwent successful ABO-compatible liver transplantation (donation after cardiac death of the donor) within 3 days of admission.
The liver explant (Image 2A) revealed progressive degenerative changes (Image 2B, Image 2C) with massive hepatic necrosis (>99%), compared with the initial biopsy (65%) obtained less than 1 week previously. Bile ductular proliferation was conspicuous, as were moderate portal lymphocytic infiltrate and venulitis. A 1.5-cm wedge of the explant was retested for HHV-6 and revealed 37,689 copies per mL (4.58 log). The 1.48-log base increase in viral load, compared with the initial specimen, is ascribed to specimen size, location, or a combination of both factors.
The qPCR result was corroborated by an outside reference center (Coppe Laboratories). At this center, in addition to confirming the presence of HHV-6 by qPCR, the variant type was identified as HHV-6B. Further, IHC testing revealed HHV-6B in the ductular epithelium (Image 2D). No evidence of HHV-6 or other etiologic agents, assessed by qPCR or IHC, were identified in the liver or plasma, bolstering support for the contention that the presence of ALF in specimen material from the patient was attributable to a localized, active infection caused by HHV-6.
The posttransplant course of treatment was complicated by pleural effusions, ascites, and pancytopenia. The effusions, which were drained for symptomatic relief, were attributed to chylous leakage and oozing from the exposed, raw surface of the liver. The fluids contained white blood cells and bacteria; however, culture results were negative. The pleural effusion tested positive for HHV-6 (5000 copies/mL).
The patient was placed on total parenteral nutrition for bowel rest and administered furosemide. The pancytopenia was evaluated with 2 separate bone marrow biopsies, the results of which revealed hypocellular marrow (5% to 20%) with scant erythropoiesis and marked myeloid and megakaryocytic hypoplasia. Both bone marrow specimens were analyzed for HHV-6 with qPCR to rule out viral-induced myelosuppression.
The first bone marrow aspirate tested negative; however, the second marrow specimen tested positive for HHV-6 (1480 copies/mL). However, due to aliquot size, definitive subclassification (HHV-6A or HHV-6B) could not be determined. Further, no HHV-6 positive cells were identified by IHC in the corresponding clot section. Thus, direct myelosuppression by viral infection was not supported. The findings in the bone marrow of the patient appeared to be attributable to the well-documented association of aplastic anemia (AA) coinciding with acute hepatitis. 3 In pediatric cases of non-A through non-E hepatitis, hematopoietic dysfunction typically occurs concomitant with the hepatitis or 1 to 7 weeks after liver transplant, 3 the latter of which was exemplified in this case. With this association in mind, we transfused the patient with platelets and treated him with granulocyte colony-stimulating factor with subsequent elevation in cell counts. Ten months after transplantation, the patient is still being treated with prophylactic and posttransplant therapeutic protocols and continues to test negative for CMV, EBV, and HHV-6 via serial peripheral blood surveillance with qPCR.
Image 1
Test results from our patient, an 11-year-old Caucasian boy. A, Hematoxylin-eosin (H&E)-stained section of liver biopsy demonstrating loss of normal hepatic architecture with submassive necrosis (central portion of image) with a mixed inflammatory infiltrate that extends into the hepatic lobules (original magnification ×100). B, Residual hepatocytes show ballooning degeneration with vacuolated, distended cytoplasm and vesicular nuclei, some of which contain large inclusions (arrowhead). Apoptotic hepatocytes were conspicuous (arrow; hematoxylineosin staining; original magnification, ×400); C, Ultrastructural analysis features recapitulated light microscopic findings; no infectious etiologic agents were identified (original magnification, ×2500).
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Laboratory Information

Clinical Specimens
Processing for light microscopy entailed tissue fixation in 10% neutral buffered-formalin, followed by standard processing and subsequent hematoxylin-eosin (H&E) staining. IHC using a monoclonal antibody directed at glycoprotein H, a late structural protein of HHV-6, was performed at a reference site (Coppe Laboratories). For electron microscopy, tissue was fixed in 2.5% glutaraldehyde and sent to Children's Hospital of Colorado, Denver, CO, for further processing, per standard protocols, and then stained with uranyl nitrate and lead citrate before examination by transmission electron microscopy.
The detection and quantification of HHV-6 genomic DNA was performed by qPCR on specimens of bone-marrow aspirates, plasma, pleural fluid, and liver specimens obtained before and after liver transplantation. 
Image 2
Gross and microscopic findings from 11-year-old Caucasian boy with HHV-6. A, Cut surface of liver resection revealing congested cut surfaces reminiscent of a nutmeg pattern (cut surface of the explanted liver shows chronic passive congestion); B, With the cellular dropout/hepatonecrosis, the blood supplied to percolate through the normally intact sinusoids is lacking a true architecture. As a result, the blood mingles with the dead/dying hepatocytes. (hematoxylin-eosin staining; original magnification, ×40). C, A brisk lymphocytic response is present in the portal regions, as is bile ductular proliferation (hematoxylin-eosin staining; original magnification ×100). D, Immunohistochemical investigation for human herpesvirus 6B showed no reactivity in focal residual hepatocytes; however, foci of positivity were identified in biliary epithelial tissue (original magnification ×200).
different clinical specimens, including fresh and frozen tissue, and provided general guidance related to proper and safe biological specimen collection, preparation, and extraction, as well as purification of nucleic acids.
DNA Detection and Quantification
The Phoenix Children's Hospital Molecular Department specializes in qualitative and quantitative real-time polymerase chain reaction (qRT-PCR) detection of many viruses, focused on providing rapid results and viral-load monitoring specifically targeting an immunocompromised patient population. This outcome is accomplished by using various in-house designed and validated polymerase chain reaction (PCR) assays according to Clinical Laboratory Improvement Amendments (CLIA) regulations (42 CFR Section 493.1253) and organic and inorganic manual, automated, and semiautomated DNA/RNA extraction procedures.
All PCR assays have been validated and verified, to extract the optimal amount of DNA/RNA from numerous specimen types, including but not limited to bone marrow, whole blood, plasma, body fluid (pleural fluid), cerebrospinal fluid (CSF), urine, tissue specimens (fresh and formalin-fixed, paraffin-embedded [FFPE]), and stool specimens, according to department standard operating procedures and within CLSI guidelines for work dealing with DNA/RNA derived from submitted clinical specimens.
Clinical specimens with unknown viral loads are quantitated by generating, storing, and referencing a standard curve or calibration run. Standard curves are generated by extracting known values/amounts of target DNA/RNA: ie, 1.0 × 10 8 copies (c) per mL in a 10-fold dilution series down to 1 × 10 4 c/mL and then running them in sets of 4 with a 0.5 tolerance, to obtain a slope of −3.3, which would indicate a perfectly efficient PCR reaction, and a line of regression or R 2 value of 1.00, which would indicate how well the regression line fits the data points. This run is used by the real-time cycler and analytical software to quantify unknowns.
The patient specimens with (initially) unknown results, if they test positive, demonstrate a positive amplification or sigmoidal curve, which crosses a threshold (CT) point (CT value). The CT value is used by the software to compare against the programmed calibration run, to quantify viral loads in a given specimen. A CT value is understood to be inversely proportional to the amount of DNA/RNA in a given specimen; therefore, a specimen that crosses the threshold, or displays an early CT value will have more target DNA/RNA present than a specimen that records a higher CT value.
When performing quantitative assays, quality control statistics are also calculated and documented on a monthly basis, to define analytic imprecision and to monitor trends over time. Statistical analysis includes mean (SD) and percent coefficient of variation (%CV).
For this case study, we extracted DNA using the bioMérieux easyMAG semiautomated nucleic acid extraction platform, according to manufacturer guidelines. Detection of HHV-6 DNA was performed using a quantitative real-time scorpion primer with integrated fluorescent FAM probe PCR assay (DiaSorin Molecular LLC). Amplification data was analyzed and viral loads calculated (copies/mL) using the Integrated Cycler Studio Software, version 6.0.0.2 (DiaSorin Molecular LLC). The Phoenix Children's Hospital Molecular Department designed, validated, and used custom oligonucleotide primers to create positive amplification controls (GenBank accession number KX595170) to run in parallel with HHV-6 qPCR assays with limits of detection (LOD) and limits of quantification (LOQ) validated and reportable from 500 to 1.3e 7 copies per mL.
The HHV-6 primers and probes employed were specific for a highly conserved region located within the HHV-6 major antigenic structural protein (p100). This specific combination enabled efficient detection and amplification of HHV-6A and HHV-6B variant nucleic acids with no evidence of detection, amplification, or cross-reactivity with DNA from other infectious agents, including HSV 1 and 2; CMV; EBV; varicella zoster virus; HHV-7 and -8; parvovirus B19; hepatitis B, C, and D viruses; human T-lymphotropic viruses 1 and 2; HIV 1 and 2, BK virus, Toxoplasma gondii, and Tropheryma whipplei. 4 HHV-6 variant speciation and quantification was performed at a reference center (Coppe Laboratories). Results of HHV-6 genomic DNA detection and quantitation of viral levels obtained through qPCR are provided in Table 1 , in order of testing.
Discussion
HHV-6 is a member of the β-Herpesviridae subfamily and was first detected in human peripheral blood in 1986. 5 Similar to other herpes viruses, HHV-6 can reside latent within the host with potential for subsequent reactivation, especially in an immunocompromised host. 6 HHV-6 has 2 known variants, namely, HHV-6A and HHV-6B,which are distinguished by biological characteristics, monoclonal antibody reactivity, and endonuclease restriction patterns; however, the term HHV-6 is commonly used in reference to both species. 2, 6 HHV-6 is a lymphotropic virus with a predilection for lymphocytes and monocytes and uses the CD46 cell surface receptor to gain access to and infect other cell types, including glial cells, fibroblasts, and endothelial and epithelial cells. As a consequence, HHV-6 can be found in the brain, salivary glands, tonsils, lungs, kidney, and liver. 7 Primary infection with HHV-6 typically occurs in the first 2 years of life; nearly 90% of adults harbor serological evidence of previous infection. 6, 7 The mode of transmission for HHV-6A is currently unknown, to our knowledge; its counterpart replicates in the salivary glands and thus, HHV-6B is thought to be transmitted through oral secretions. 7 We note that a previous analysis revealed intrauterine HHV-6 transmission by detection of the virus in fetal organs by PCR, 8 whereas another study showed excretion of HHV-6 in the female genital tract, suggesting a possible perinatal transmission and resulting in the development of neonatal infections. 9 We find it interesting that both variants of HHV-6 can become integrated into the genetic make-up of the host. 7 This phenomenon is characterized by assimilation of the entire HHV-6 genome into the telomere of the chromosome, resulting in the viral DNA being integrated into germline constituents. Chromosomally integrated HHV-6 (ciHHV-6) can be propagated in Mendelian fashion with a 50% chance of being passed to the offspring. 10 Aside from genetic transmission, ciHHV-6 cells may be disseminated through allogeneic hematopoietic stem-cell and solid-organ transplantation. 10 Chromosomally integrated HHV-6 is rare, affecting 0.8% to 2% of the population. 6 Primary HHV-6 infections may present as an asymptomatic illness or febrile syndrome accompanied by a maculopapular rash known as exanthem subitum caused by HHV-6B. 7 HHV-6A appears to be more neurotropic and associated with neurologic sequelae, notably in immunocompromised patients; 7 however, liver dysfunction resulting from acute HHV-6A infection after cardiac transplant has been reported. 11 Although usually self-limited, HHV-6 has also been associated with otitis media, gastrointestinal symptoms, respiratory distress, seizures, encephalitis, autoimmune conditions, Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome, myocarditis, and ALF. 6, 7, 12 Regarding ALF, it has been established that the herpes virus family, as a group, is known to cause liver derangement, such as CMV, HSV, and EBV, as well as to contribute to FH. 1 However, ALF associated with HHV-6 appears to be a rare occurrence. The first reported case (1990) described a 3-month-old Japanese boy with fulminant hepatic failure. 13 Since that time, only a few anecdotal reports and case series have documented HHV-6 as the etiologic agent in non-A through non-E hepatitis involving the pediatric or adult population.
1,2,6,14-25
Multiple testing methodologies can be employed to ascertain the presence of HHV-6, including serology, culture, antigenemia, IHC, and nucleic acid amplification assays. 7 Serology is hampered in its inability to detect clinically relevant disease by the simple ubiquitous nature of HHV-6, whereas culture methods are labor intensive, time consuming, and typically not amenable to real-time patient treatment. 7 Adjunct tests, such as PCR and IHC, can efficiently identify viral markers in tissue specimens. These methods can also indicate active versus latent infections and allow for differentiation between the variants of HHV-6. 7 Molecular assays that can detect and amplify HHV-6 nucleic acids are the most common laboratory methods currently used and can be applied to blood or tissue specimens. 7 We used IHC and qPCR methods in the present case.
According to the HHV-6 Foundation (https://hhv-6founda-tion.org/patients/hhv-6-testing-for-patients), quantitative PCR is a reliable means to demonstrate active versus latent HHV-6 in tissue biopsies and whole blood or plasma specimens. Testing methods accomplish this by demonstrating 200 copies per mL or more of HHV-6 in whole blood, any detection in plasma, or high viral copy numbers in tissue biopsies, all of which are indicative of an overall active viral process but not necessarily an active infection.
HHV-6 was not detected immunohistochemically in the initial needle biopsy; however, HHV-6B was present in the subsequent explanted liver, where it was localized in the biliary epithelium. Authors 2, 6, 14, 22 have noted identification of the virus using hybridization or IHC techniques in the hepatic inflammatory infiltrate, hepatocytes, biliary epithelium, and portal vein endothelium. Analogous to previous reports, 6, 25 no HHV-6 was present in the hepatocytes of the initial or explanted liver specimens. Those authors contend that the lack of IHC positivity in the biopsy may be attributed to specimen retrieval or the stage(s) of viral replication at the time of the surgical intervention. The marker used in the case of our patient targeted a late structural glycoprotein (gamma H), which may not have been expressed in the residual intact hepatocytes. Thus, if the virus was in the earlier stages of replication, the late structural protein targeted by this particular antibody would not be expressed, resulting in a lack of immunoreactivity. Further, one would not expect viral replication in dead hepatocytes; therefore, no detection was noted in the necrotic hepatocellular regions in the core or explant specimens.
Our findings of the virus in the biliary epithelium and not the hepatocytes are congruent with previously reported investigations linking ALF with HHV-6 infection. 6, 25 No HHV-6
was documented in the plasma specimens. Nevertheless, the aggregate findings of the viral load levels from the initial biopsy, in conjunction with an elevated viral copy number and IHC detection of HHV-6B in the liver explant, were consistent with demonstrating a localized, active HHV-6 infection resulting in ALF.
Similar to this case report, several studies have linked HHV-6 with acute liver failure. In one cohort, HHV-6 antigens were identified in 80% of analyzed livers with ALF of unknown etiology. 14 Also, Schwarz et al 26 conducted a multicenter investigation of pediatric ALF and reported that HHV-6 was the most frequently identified virus. This finding was supported in a separate analysis by Ishikawa et al, 1 wherein HHV-6 was detected in all pediatric patients with non-A, non-B and non-C FH. Further, this group noted that HHV-6 more commonly resulted in FH than CMV or EBV did. 1 However, the actual incidence of HHV-6 is currently unknown because screening for this agent is not typically performed. 6 In fact, many pediatric patients are not fully tested for viral etiologies, especially HHV-6. 6 The lack of broad viral screening in clinical practice is counterintuitive, given that the etiology of FH is not identified in 40% to 50% of patients. 1 Also, clinical outcomes are largely dependent on the inciting agent; viral and unknown etiologies typically portend worse short-term transplant-free survival, compared with drug-or hepatitis-A-induced ALF. 6 Every effort should be made to identify the causative agent of liver failure, to provide optimal treatment for patients. Despite this, currently there are no consensus guidelines or algorithms for laboratory testing, to our knowledge. Our standard practice involves analyzing tissue specimens for common pathogens and etiologies, including CMV, EBV, HSV 1 and 2, hepatitis A through E, α-1 antitrypsin deficiency, Wilson disease, and autoimmune hepatitis. If the results are negative, testing for less-common agents, such as HHV-6, HIV, HTLV 1 and 2, RSV, Coccidioides, parvovirus B19, influenza A and B, BK virus, Toxoplasma gondii, and Tropheryma whipplei, is performed. Initial processing of liver biopsies includes storage of a snap-frozen aliquot in a metal-free container for iron/copper quantification and fixation of an aliquot in glutaraldehyde for electron-microscopic examination.
To this end, we used a robust panel of testing to assess for possible toxicological, metabolic, and infectious etiologies for the ALF harbored by our patient; the only identifiable cause proved to be HHV-6B. However, we do not have data on the HHV-6 antibody levels of the patient. Such data would have helped us determine whether this was a primary infection, which is unlikely given his age, or whether this was a reactivation of the virus, which has been reported to occur if the patient is reinfected after the age of 2 years. 1 We were intrigued that the patient reported a rash and febrile episodes, which were suggestive of exanthem subitum. It has been documented 27 that detection of HHV-6
in the blood is a hallmark of active viral infection; however, this finding may not always be present: none of the plasma specimens from our patient tested positive for HHV-6.
A similar dissociation between nondetectable HHV-6 viremia in patients with HHV-6-induced liver failure has been documented. 24, 25, 28, 29 Testing for possible activation of ciHHV-6 was not performed because these patients typically present with notable viremia levels of greater than 1 million copies per mL; such a finding was not present in this case. An association between HHV-6 and indeterminate ALF has been established. However, the pathogenic mechanisms involving HHV-6 in hepatic derangement remains suggestive only because viral reactivation could be elicited by an unknown agent that induces ALF with HHV-6 exerting effects after the onset of liver dysfunction. 15 In the present case, our patient demonstrated previous exposure to EBV. Nevertheless, his levels before and after transplantation failed to show evidence of active infection. This finding imparted doubt that the synergistic effects of the 2 viruses led to the hepatic failure experienced by this patient. Some authors speculate that HHV-6 infection may influence immunologic events, such as the elaboration of cytokines from HHV-6 infected cells, which disrupts hepatic homeostasis, leading to ALF. 15, 26 Current consensus says that FH is the direct result of marked apoptosis of hepatocytes induced by overproduction of cytokines, such as tumor necrosis factor, and free radicals, such as nitric oxide, which are ultimately released in response to viral infection. 26 The histologic findings of hepatonecrosis and a marked inflammatory infiltrate in our case support this hypothesis and were similar to characteristics documented in other reports that attributed ALF to HHV-6 infection. 6, 14, 24, 28 Further, the IHC expression of glycoprotein H, a late structural protein of HHV-6, 6 showed marked reactivity in the ductular epithelium of the liver, supporting an actively replicating viral process.
Identifying the etiologic agent in cases of FH can prove problematic. Indeed, one of the major limitations encountered in this case involved the inability to demonstrate HHV-6 in the blood/plasma of our patient, despite analyzing serial specimens before and after transplantation. A study by Suga et al 29 showed that HHV-6 was demonstrated in the blood as many as 5 days after the presentation of examthem a subitum and that its identification in the blood suggested an active infection. However, testing for HHV-6 was not initially performed when our patient reported a rash, suggestive of exanthema subitum, in the weeks before he presented to our institution. Although we did not document active viremia, our analyses for multiple etiologic agents (toxicological, infectious, autoimmune, etc.) ruled out all possible causes except HHV-6, which supported an active, local infection of the liver. Although uncommon, this dissociation has been previously described in patients with ALF attributed to HHV-6. 24, 25, 28, 29 Failure to demonstrate the presence of the virus in hepatocytes of the biopsy or the explant via IHC could be viewed as a limiting factor. As described earlier herein, the authors attributed this lack of immunoreactivity to specimen gathering, the antibody used for detection, and massive hepatic necrosis. The antibody used in this case targets a late structural protein. If the virus is in the earlier stages of replication, it will go undetected because the target epitope would not be expressed. Further, one would not anticipate viral replication in dead hepatocytes, which were the major component of the biopsy and the explant. Lending support to the diagnosis of HHV-6-induced ALF is the virus localization in the biliary epithelium-a finding that had been reported previously. 6, 25 A third limiting factor in our analysis of this case was the failure to demonstrate virion particles in the tissue submitted for EM, which could be explained by sampling error.
At present, no United States Food and Drug Administration (FDA)-approved antiviral protocols exist for HHV-6; historically, these infections have been treated with ganciclovir, foscarnet, and/or cidofovir because HHV-6A and HHV-6B are resistant to acyclovir and penciclovir. 7 Most of these infections are subclinical and transient, so treatment is generally not recommended. 7 However, in the setting of encephalitis, hepatitis, or liver allograft dysfunction, determination of possible HHV-6 infection is clinically warranted.
7
No reports document the efficacy of early treatment with antivirals in precluding liver transplant. 7 Moreover, previous studies 28, 30 have shown that pretransplant HHV-6 infection may be a risk factor for posttransplant HHV-6 infection in the graft. Further investigation is required to determine the necessity for prophylactic therapy after transplantation stemming from complications associated with HHV-6.
7,16
Conclusion
The etiology of non-A through non-E ALF is not identified in 51% of cases and is associated with significant mortality, even after liver transplantation. 28 Although the pathogenic mechanisms of HHV-6 are not fully understood, the association of this virus and ALF has been established and linked to serious complications, including death. 15 Despite this finding, many healthcare professionals fail to investigate all the viral etiologies that could instigate hepatic dysfunction, especially HHV-6. 28 We advocate not only screening for common and uncommon viral etiologies associated with liver dysfunction but also reporting cases of HHV-6-associated FH/ALF. Doing so would increase awareness of HHV-6, including its role and prevalence in liver disease. LM DOI: 10.1093/labmed/lmx088 CO), for providing technical assistance with ultrastructural images; and Coppe Laboratories (Waukesha, WI) for performing specimen analysis for HHV-6, including qPCR and immunohistochemistry with interpretation, and providing antibody information.
